Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells

Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells Publisher Pubmed

Keshtvarz M¹ ; Salimian J² ; Yaseri M³ ; Bathaie SZ⁴ ; Rezaie E⁵ ; Aliramezani A¹ ; Norouzbabaei Z⁶ ; Amani J⁵ ; Douraghi M^{1, 7}

Show Affiliations

1. Division of Microbiology, Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2. Chemical Injuries Research Center, Baqiyatallah, University of Medical Sciences, Tehran, Iran
3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Clinical Biochemistry, Tarbiat Modares University, Tehran, Iran
5. Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Vanak Sq. Molasadra St, Tehran, Iran
6. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
7. Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Immunotherapy Published:2017

Abstract

Aim: AFn14R can serve as an ideal target for cancer immunotherapy. Here, a combined bioinformatic and experimental approach was applied to characterize an immunotoxin consisting of single-chain variable fragment antibody that targets Fn14 and a toxin fragment (PE38). Methods & Results: Flow cytometry results showed that the rate of PE38-P4A8 binding to Fn14 was approximately 60 and 40% in HT-29 and A549 cells, respectively. Moreover, 1 ng/l of immunotoxin was able to lyse approximately 53 and 41% of HT-29 and A549, respectively. PE38-P4A8 showed stability in mouse serum (∼90%) after 3-h incubation. Most importantly, using bioinformatics for determining the structure and function of fusion proteins can be very helpful in designing of experiments. Conclusion: Coupled with bioinformatics, experimental approaches revealed that PE38-P4A8 could be used as a promising therapeutic agent for cancer cells expressing Fn14. © 2017 Future Medicine Ltd.

Related Docs

View other Related Docs

1. A Novel Shiga Based Immunotoxin Against Fn-14 Receptor on Colorectal and Lung Cancer, International Immunopharmacology (2022)

2. Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (Cls) and Recently Developed Countering Strategies, Current Molecular Medicine (2018)

3. A Review on the Types of Immunotoxins and Their Use in Cancer Treatment: Review Article, Tehran University Medical Journal (2018)

4. Design of a Multi-Epitope Vaccine Against Sars-Cov-2 Using Immunoinformatics Approach, International Journal of Biological Macromolecules (2020)

5. The Importance of the Non-Active Site and Non-Periodical Structure Located Histidine Residue Respect to the Structure and Function of Exo-Inulinase, International Journal of Biological Macromolecules (2017)

6. Optimized Protocol for Soluble Prokaryotic Expression, Purification and Refolding of the Human Inhibin Α Subunit, a Cysteine Rich Peptide Chain, Human Antibodies (2020)

7. Improvement of Solubility and Refolding of an Anti-Human Epidermal Growth Factor Receptor 2 Single-Chain Antibody Fragment Inclusion Bodies, Research in Pharmaceutical Sciences (2018)

8. A Simplified Process for Purification and Refolding of Recombinant Human Interferon-Α2b, Iranian Biomedical Journal (2022)

Experts (# of related papers)

View all Related Experts

Mohammad Reza Fazeli (2)

Mohammad Hossein Modarressi (1)

Style	Citing Format
MLA	Keshtvarz M, et al.. "Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells." Immunotherapy, vol. 9, no. 5, 2017, pp. 387-400.
APA	Keshtvarz M, Salimian J, Yaseri M, Bathaie SZ, Rezaie E, Aliramezani A, Norouzbabaei Z, Amani J, Douraghi M (2017). Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells. Immunotherapy, 9(5), 387-400.
Chicago	Keshtvarz M, Salimian J, Yaseri M, Bathaie SZ, Rezaie E, Aliramezani A, Norouzbabaei Z, Amani J, Douraghi M. "Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells." Immunotherapy 9, no. 5 (2017): 387-400.
Harvard	Keshtvarz M et al. (2017) 'Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells', Immunotherapy, 9(5), pp. 387-400.
Vancouver	Keshtvarz M, Salimian J, Yaseri M, Bathaie SZ, Rezaie E, Aliramezani A, et al.. Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells. Immunotherapy. 2017;9(5):387-400.
BibTex	@article{ author = {Keshtvarz M and Salimian J and Yaseri M and Bathaie SZ and Rezaie E and Aliramezani A and Norouzbabaei Z and Amani J and Douraghi M}, title = {Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells}, journal = {Immunotherapy}, volume = {9}, number = {5}, pages = {387-400}, year = {2017} }
RIS	TY - JOUR AU - Keshtvarz M AU - Salimian J AU - Yaseri M AU - Bathaie SZ AU - Rezaie E AU - Aliramezani A AU - Norouzbabaei Z AU - Amani J AU - Douraghi M TI - Bioinformatic Prediction and Experimental Validation of a Pe38-Based Recombinant Immunotoxin Targeting the Fn14 Receptor in Cancer Cells JO - Immunotherapy VL - 9 IS - 5 SP - 387 EP - 400 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract